QRxPharma Limited - Product Pipeline Review - 2014

Date: June 15, 2014
Pages: 42
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: QD8999AF0F5EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘QRxPharma Limited - Product Pipeline Review - 2014’, provides an overview of the QRxPharma Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of QRxPharma Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of QRxPharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of QRxPharma Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the QRxPharma Limited’s pipeline products
Reasons to buy
  • Evaluate QRxPharma Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of QRxPharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the QRxPharma Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of QRxPharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of QRxPharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of QRxPharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
QRxPharma Limited Snapshot
QRxPharma Limited Overview
Key Information
Key Facts
QRxPharma Limited - Research and Development Overview
Key Therapeutic Areas
QRxPharma Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
QRxPharma Limited - Pipeline Products Glance
QRxPharma Limited - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
QRxPharma Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
QRxPharma Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
QRxPharma Limited - Drug Profiles
(morphine + oxycodone) IR
Product Description
Mechanism of Action
R&D Progress
(morphine + oxycodone)
Product Description
Mechanism of Action
R&D Progress
(morphine + oxycodone) CR
Product Description
Mechanism of Action
R&D Progress
Q-8008
Product Description
Mechanism of Action
R&D Progress
Q-8009
Product Description
Mechanism of Action
R&D Progress
T-9001
Product Description
Mechanism of Action
R&D Progress
V-0801
Product Description
Mechanism of Action
R&D Progress
QRxPharma Limited - Pipeline Analysis
QRxPharma Limited - Pipeline Products by Target
QRxPharma Limited - Pipeline Products by Route of Administration
QRxPharma Limited - Pipeline Products by Molecule Type
QRxPharma Limited - Pipeline Products by Mechanism of Action
QRxPharma Limited - Recent Pipeline Updates
QRxPharma Limited - Dormant Projects
QRxPharma Limited - Company Statement
QRxPharma Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

QRxPharma Limited, Key Information
QRxPharma Limited, Key Facts
QRxPharma Limited - Pipeline by Indication, 2014
QRxPharma Limited - Pipeline by Stage of Development, 2014
QRxPharma Limited - Monotherapy Products in Pipeline, 2014
QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
QRxPharma Limited - Filing rejected/Withdrawn, 2014
QRxPharma Limited - Phase III, 2014
QRxPharma Limited - Phase II, 2014
QRxPharma Limited - Preclinical, 2014
QRxPharma Limited - Pipeline by Target, 2014
QRxPharma Limited - Pipeline by Route of Administration, 2014
QRxPharma Limited - Pipeline by Molecule Type, 2014
QRxPharma Limited - Pipeline Products by Mechanism of Action, 2014
QRxPharma Limited - Recent Pipeline Updates, 2014
QRxPharma Limited - Dormant Developmental Projects,2014
QRxPharma Limited, Subsidiaries

LIST OF FIGURES

QRxPharma Limited - Pipeline by Top 10 Indication, 2014
QRxPharma Limited - Pipeline by Stage of Development, 2014
QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
QRxPharma Limited - Pipeline by Top 10 Target, 2014
QRxPharma Limited - Pipeline by Top 10 Route of Administration, 2014
QRxPharma Limited - Pipeline by Top 10 Molecule Type, 2014
QRxPharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2014
Skip to top


Mesoblast Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 51 pages
Pharminox Limited - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 21 pages
Cellmid Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 30 pages
Immunocore Limited - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 33 pages

Ask Your Question

QRxPharma Limited - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: